GLP-1 RA for Colorectal Cancer

This trial aims to determine whether semaglutide, a GLP-1 Receptor Agonist, can be safely combined with standard chemotherapy to treat certain advanced cancers, such as metastatic colorectal cancer. Researchers seek to discover if adding semaglutide enhances the effectiveness of standard cancer treatments while maintaining patient safety. The trial targets individuals with specific types of advanced cancers who have a body mass index (BMI) over 25 and are undergoing their first set of cancer treatments. As an Early Phase 1 trial, this research focuses on understanding the treatment's effects in people, offering participants a chance to contribute to groundbreaking cancer treatment development.

The trial information does not specify if you need to stop taking your current medications. However, it does mention that patients on insulin are excluded, and those with HBV must be on antiviral therapy. It's best to discuss your specific medications with the trial team.

Research has shown that semaglutide, a type of medication, is generally safe for use. Large studies involving over 60,000 participants found no increased risk of colorectal cancer compared to a placebo. In fact, these medications may lower the risk of developing colorectal cancer. Some studies report a significant decrease in colon cancer risk with these drugs. Additionally, the FDA has not identified any safety concerns related to colorectal cancer with this type of medication. Overall, these findings suggest semaglutide is well-tolerated, but this trial is needed to confirm its safety when used with chemotherapy for certain cancers.¹²³⁴⁵

Researchers are excited about using Semaglutide, a GLP-1 receptor agonist, for treating colorectal cancer because it offers a unique approach compared to the standard treatments like FOLFOX or FOLFIRI. Unlike traditional chemotherapy, which directly targets cancer cells, Semaglutide works by mimicking a hormone that regulates insulin, potentially influencing cancer growth indirectly by affecting metabolism and weight. This novel mechanism provides a fresh angle in tackling cancer, particularly for patients with a higher BMI, and could complement existing therapies to improve outcomes.

Research has shown that medications like semaglutide, known as GLP-1 receptor agonists, may help reduce the risk and slow the progression of certain cancers, such as colorectal, pancreatic, and liver cancer. In this trial, participants with metastatic colorectal adenocarcinoma will receive semaglutide alongside standard-of-care (SOC) treatment, which may include FOLFOX or FOLFIRI with or without bevacizumab. For pancreatic cancer, participants will receive semaglutide with SOC treatment, specifically modified FOLFIRINOX. In liver cancer, semaglutide will be administered with SOC treatment, specifically Tremelimumab/Durvalumab. This evidence suggests that semaglutide might effectively manage these cancers along with standard treatments.²⁵⁶⁷⁸